

Investor Newsletter

Issue 06 2019



MPSC 2019 Annual General Meeting Held

MicroPort Scientific Corporation (HK: 853) ("MPSC") 2019 Annual General Meeting ("AGM") was held on June 13 in its Shanghai headquarters. The meeting was chaired by Dr. Zhaohua Chang, Chairman, Executive Director and Chief Executive Officer of MPSC. Board of Directors including Dr. Zhaohua Chang, Non-executive Directors Hiroshi Shirafuji and Norihiro Ashida, Independent Non-executive Directors Dr. Guoen Liu, Jonathan Chou and Chunyang Shao, attended the meeting. According to Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited, all of the 12 ordinary resolutions were taken by poll. All the proposed resolutions were passed by votes representing more than half of the total number of votes held by the attending shareholders and proxies having valid voting rights.

During the meeting, Dr. Zhaohua Chang, MPSC Chief Marketing Officer Bo Peng, MPSC Chief Finance Officer Martin Sun, MPSC Chief Technology Officer Dr. Qiyi Luo, MPSC Chief International Business Officer Jonathan Chen, and Benoît Clinchamps, President of MicroPort CRM, answered questions raised by shareholders.



MicroPort® Attends the 13th Oriental Congress of Cardiology (OCC 2019)

The 13th Oriental Congress of Cardiology (OCC 2019) was held at the Shanghai Expo Center, bringing together about 2,000 healthcare professionals from 21 countries and regions as speakers and honored guests as well as over 13,000 attendees. Shanghai MicroPort Medcial (Group) Co., Ltd. ("MicroPort") presented Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Firefighter™ PTCA Balloon Dilation Catheter ("Firefighter™"), which attracted wide attention from Chinese and overseas cardiologists.



During the live case session on June 1, Prof. Sidney Lo from Australia, Prof. Toshiya Muramatsu from Japan and Prof. Fenghua Ding from Rui Jin Hospital applied Firefighter™ in three operations performed at the catheterization laboratory of Rui Jin Hospital. A total of three Firefighter™ systems, with two 1.0*6mm and one 1.0*10mm, were used in the live cases under the topic of complex lesions. The ultra-low profile and excellent crossability of Firefighter™ won praises from the three operators.

During OCC 2019, the MicroPort® booth comprehensively showcased multiple innovative achievements of MicroPort® in cardiology, which were led by the interventional cardiology products in combination with the products in the fields of cardiac rhythm management and electrophysiology, and structural heart.

MicroPort® Orthopedics Holds the Second Edition of SuperPATH® Super+User Better Together

Zhenjiang, China – On June 14-15, 2019, Shanghai MicroPort Orthopedics MedTech Co., Ltd. (“MicroPort® Orthopedics”) hosted the second edition of SuperPATH® Super+User Better Together in Zhenjiang, China, bringing together Mr. Jimmy Chow M.D., who is the inventor of Supercapsular Percutaneously Assisted Total Hip Arthroplasty (“SuperPath®”) and from the Abrazo Scottsdale Campus in the US, as well as members of the “SuperPATH® Super+User 100 Cases Club” to conduct scientific exchanges on the cutting-edge techniques of hip replacement.

The event was composed of the secessions named “SuperPATH® Live Case”, “SuperPATH® Discussions” and “SuperPATH® Consensus”. After the live cases, Mr. Jimmy Chow M.D. spoke of the development history of the SuperPATH® technique, its skills and follow-up studies. He said: “SuperPATH® is a safe and reliable technique, which can easily be converted to conventional posterolateral approach intraoperatively. With 15-year clinical application, it has a good deal of peer-reviewed supporting study results published by healthcare professionals from different countries.”



Since the establishment of the SuperPATH® Super+User 100 Cases Club in 2018, its ranks keep growing. More and more orthopedic healthcare professionals have been engaged in the exchanges and promotion of the SuperPATH® technique on this platform, while MicroPort® Orthopedics uses the platform to provide the healthcare professionals with the scientific information and related resources at the forefront of international researches. On June 16, the SuperPATH® Joint Reconstruction Micro-Invasive Technique International Training Center (“the Center”) was officially set up at the First Affiliated Hospital of Soochow University.

Tubridge® NeuroTech Donates a Tubridge® Device to Successfully Save the Life of a Patient Diagnosed with Multiple Intracranial Aneurysms

On May 30, 2019, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") donated a Tubridge® Vascular Reconstruction Device ("Tubridge®") to help a neurovascular surgical team from Qilu Hospital of Shandong University successfully perform an operation on a patient diagnosed with multiple intracranial aneurysms. The team was led by Prof. Haidong Wang from the hospital.

Prof. Donghai Wang said that Tubridge® was used due to its epitomizing outstanding Chinese-made medical devices. The device cures the cerebral aneurysm by effectively diverting the blood flow based on hemodynamics and gradually repairing aneurysmal neck. The treatment of four aneurysms with one Tubridge® proved to be an optimal solution in this case featuring multiple aneurysms. The innovative Tubridge® resulting from 12-year independent development by MicroPort® NeuroTech has demonstrated high blocking rate, safety, and low recurrence rate in the treatment of big and huge intracranial aneurysms. It has also helped take on the challenges confronted by conventional therapies, including high cost and unsatisfactory prognosis.

As a company never hesitates to shoulder social responsibility, MicroPort® NeuroTech has made a few donations to patients. MicroPort® NeuroTech adheres to the credo of "Save the lives of patients" and joins forces with healthcare professionals with patient care to support charity work and help patients regain hope.



MPSC Makes the List of China's **500 Most Valuable Brands**, Becoming the First from the Medical Device Industry

On June 26, the 16th edition of the World Brand Summit under the theme of Global Leadership and China's Brand Rebuilding was held in Beijing, China. At the summit, World Brand Lab released the 2019 China's 500 Most Valuable Brands report. MPSC is honored to be the first company from the medical device industry to make the list, which has been published annually since 2004, with a brand value worth 7.8 billion yuan. The report tracks three indicators: financial results, brand strength and consumer behavior analysis.

World Brand Lab is the world's leading independent brand-valuation and research firm. It is headquartered in New York, US and chaired by Professor Robert Mundell from Columbia University, who is 1999's Nobel laureate in economics. World Brand Lab is acclaimed as one of the world's top three brand valuation institutions. It has released the China's 500 Most Valuable Brands list in the past 16 years, which has become a weathervane for the development and power of Chinese brands.



Investor Newsletter

Issue **06** 2019



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com